These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 27608310)

  • 1. [Approach to directed therapy after knowledge of the isolate: carbapenemase-producing Enterobacteriaceae, multidrug-resistant Pseudomonas aeruginosa and carbapenem-resistant Acinetobacter baumannii].
    Martínez JA
    Rev Esp Quimioter; 2016 Sep; 29 Suppl 1():31-4. PubMed ID: 27608310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D β-lactamases.
    Mushtaq S; Vickers A; Woodford N; Livermore DM
    J Antimicrob Chemother; 2017 Jun; 72(6):1688-1695. PubMed ID: 28333319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid Blue-Carba test: reduction in the detection time of carbapenemases performed from a 4-hour bacterial lawn.
    Nastro M; Ayora M; García S; Vay C; Famiglietti Á; Rodriguez CH
    J Chemother; 2017 Jun; 29(3):150-153. PubMed ID: 27347714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiological, Physiological, and Molecular Characteristics of a Brazilian Collection of Carbapenem-Resistant Acinetobacter baumannii and Pseudomonas aeruginosa.
    Dias VC; Resende JA; Bastos AN; De Andrade Bastos LQ; De Andrade Bastos VQ; Bastos RV; Diniz CG; Da Silva VL
    Microb Drug Resist; 2017 Oct; 23(7):852-863. PubMed ID: 28437232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases.
    Sader HS; Rhomberg PR; Flamm RK; Jones RN; Castanheira M
    J Antimicrob Chemother; 2017 Jun; 72(6):1696-1703. PubMed ID: 28333332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
    Burgess DS; Frei CR
    J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of multidrug-resistant Gram-negative infections in children.
    Hsu AJ; Tamma PD
    Clin Infect Dis; 2014 May; 58(10):1439-48. PubMed ID: 24501388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging resistant Gram-negative aerobic bacilli in hospital-acquired infections.
    Kunz AN; Brook I
    Chemotherapy; 2010; 56(6):492-500. PubMed ID: 21099222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy.
    Zavascki AP; Carvalhaes CG; Picão RC; Gales AC
    Expert Rev Anti Infect Ther; 2010 Jan; 8(1):71-93. PubMed ID: 20014903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-drug resistant Pseudomonas aeruginosa and Acinetobacter baumannii infections among hospitalized patients: risk factors and outcomes.
    Shanthi M; Sekar U
    J Assoc Physicians India; 2009 Sep; 57():636, 638-40, 645. PubMed ID: 20214000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stable carbapenem susceptibility rates among multidrug-resistant Acinetobacter spp. strains in a setting of high prevalence of carbapenem-resistant Pseudomonas aeruginosa.
    Zavascki AP; Soares FC; Superti SV; Silbert S; Silva FM; Barth AL
    Int J Antimicrob Agents; 2007 Aug; 30(2):187-9. PubMed ID: 17452093
    [No Abstract]   [Full Text] [Related]  

  • 12. Associations between carbapenem use, carbapenem-resistant Pseudomonas aeruginosa, and carbapenem-resistant Acinetobacter baumannii.
    Apisarnthanarak A; Jitpokasem S; Mundy LM
    Infect Control Hosp Epidemiol; 2013 Nov; 34(11):1235-7. PubMed ID: 24113616
    [No Abstract]   [Full Text] [Related]  

  • 13. Is There a Carbapenem MIC Cutoff Value That Distinguishes Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem Non-Susceptible Pseudomonas and Acinetobacter Isolates?
    Tamma PD; Wang R; Lewis S; Opene BNA; Simner PJ
    Infect Control Hosp Epidemiol; 2017 Nov; 38(11):1378-1379. PubMed ID: 28965496
    [No Abstract]   [Full Text] [Related]  

  • 14. [Laboratory detection of carbapenemase-producing Enterobacteriaceae].
    Cercenado E
    Rev Esp Quimioter; 2015 Sep; 28 Suppl 1():8-11. PubMed ID: 26365726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular characterization of carbapenemase production among gram-negative bacteria in saudi arabia.
    Memish ZA; Assiri A; Almasri M; Roshdy H; Hathout H; Kaase M; Gatermann SG; Yezli S
    Microb Drug Resist; 2015 Jun; 21(3):307-14. PubMed ID: 25569024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of antimicrobial stewardship in curbing carbapenem resistance.
    Bogan C; Marchaim D
    Future Microbiol; 2013 Aug; 8(8):979-91. PubMed ID: 23902145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.
    Timurkaynak F; Can F; Azap OK; Demirbilek M; Arslan H; Karaman SO
    Int J Antimicrob Agents; 2006 Mar; 27(3):224-8. PubMed ID: 16464562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Infectious diseases caused by carbapenemase-producing Enterobacteriaceae--a particular challenge for antibacterial therapy].
    Stock I
    Med Monatsschr Pharm; 2014 May; 37(5):162-72; quiz 173-4. PubMed ID: 24908928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. "Future" threat of gram-negative resistance in Singapore.
    Tan TT
    Ann Acad Med Singap; 2008 Oct; 37(10):884-90. PubMed ID: 19037523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology.
    Poirel L; Nordmann P
    Clin Microbiol Infect; 2006 Sep; 12(9):826-36. PubMed ID: 16882287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.